ETHIC Act
Summary
What This Bill Does
The ETHIC Act addresses pharmaceutical patent thickets in drug and biologic litigation. In infringement actions under 35 U.S.C. 271(e), a patent owner suing a generic drug applicant, 505(b)(2) applicant, biosimilar applicant, approved generic holder, licensed biosimilar holder, or seller/importer of those products may assert no more than one patent per Patent Group. A Patent Group is a set of commonly owned patents or applications tied together through terminal disclaimers under section 253. Once the plaintiff asserts a patent from that group against that party, it may not bring additional actions asserting other patents from the same group against the same party. The bill applies to applications submitted on or after enactment.
Who Benefits and How
Generic drug applicants benefit because brand plaintiffs cannot stack multiple terminally disclaimed patents from the same Patent Group in one 271(e) case. Biosimilar manufacturers benefit because repeat suits from the same Patent Group against the same party are barred. Patients benefit if fewer patent-thicket suits speed lower-cost generic or biosimilar competition. Health insurers benefit if reduced litigation barriers make lower-priced follow-on drugs available sooner.
Who Bears the Burden and How
Brand drug patent holders lose litigation leverage from asserting multiple commonly owned terminally disclaimed patents in the same group. Biologic sponsors face the same one-patent-per-group limit when suing biosimilar applicants or sellers. Patent litigation attorneys must restructure 271(e) case strategy around Patent Group limits. Federal court judges must police Patent Group definitions and repeat-action bars in drug and biologic cases.
Key Provisions
- Limits 271(e) infringement actions to one patent per Patent Group against covered generic or biosimilar parties.
- Blocks additional actions asserting patents from the same Patent Group against the same party.
- Defines Patent Group using commonly owned patents or applications connected by terminal disclaimers.
- Applies the litigation limit to drug and biologic applications submitted on or after enactment.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Limits Hatch-Waxman and biosimilar infringement suits to one patent per Patent Group and bars repeat suits from the same group against the same generic or biosimilar party.
Key Policy Areas
Patents, Prescription Drugs, Competition
Primary Purpose
Limits Hatch-Waxman and biosimilar infringement suits to one patent per Patent Group and bars repeat suits from the same group against the same generic or biosimilar party.
Policy Domains
Resolution provisions
Identified Gains
- Generic drug applicants
- Biosimilar manufacturers
- Patients
- Health insurers
Identified Costs
- Brand drug patent holders
- Biologic sponsors
- Patent litigation attorneys
- Federal court judges
Sponsors
Legislative Progress
In CommitteeMr. Arrington (for himself, Mr. Doggett, Mr. Issa, Ms. Jayapal, …
Referred to the House Committee on the Judiciary.
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Biosimilar manufacturers, Brand drug patent holders, Generic drug applicants
Positive-direction: Biosimilar manufacturers, Generic drug applicants
Negative-direction: Brand drug patent holders
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology